Sentry Investment Management LLC reduced its stake in shares of Medtronic plc. (NYSE:MDT) by 2.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 107,136 shares of the medical technology company’s stock after selling 3,231 shares during the period. Sentry Investment Management LLC’s holdings in Medtronic were worth $8,651,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Captrust Financial Advisors acquired a new stake in shares of Medtronic during the second quarter worth $384,000. Wesbanco Bank Inc. lifted its stake in shares of Medtronic by 3.1% during the second quarter. Wesbanco Bank Inc. now owns 10,170 shares of the medical technology company’s stock worth $903,000 after buying an additional 308 shares during the period. Chilton Investment Co. LLC lifted its stake in shares of Medtronic by 6.1% during the second quarter. Chilton Investment Co. LLC now owns 26,842 shares of the medical technology company’s stock worth $2,382,000 after buying an additional 1,538 shares during the period. Moors & Cabot Inc. lifted its stake in shares of Medtronic by 0.4% during the second quarter. Moors & Cabot Inc. now owns 43,227 shares of the medical technology company’s stock worth $3,842,000 after buying an additional 178 shares during the period. Finally, Sawtooth Solutions LLC acquired a new stake in shares of Medtronic during the second quarter worth $208,000. Institutional investors and hedge funds own 81.91% of the company’s stock.

Several equities research analysts have recently commented on MDT shares. SunTrust Banks reiterated a “buy” rating and set a $96.00 price objective on shares of Medtronic in a research note on Friday, November 3rd. Bank of America upgraded shares of Medtronic from a “neutral” rating to a “buy” rating in a research note on Tuesday, January 2nd. Argus upgraded shares of Medtronic from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $81.27 to $95.00 in a research note on Tuesday, December 12th. They noted that the move was a valuation call. Oppenheimer reiterated a “buy” rating on shares of Medtronic in a research note on Thursday, December 21st. Finally, Needham & Company LLC restated a “buy” rating and set a $94.00 target price on shares of Medtronic in a research report on Thursday, November 9th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and fifteen have issued a buy rating to the stock. Medtronic has a consensus rating of “Buy” and a consensus target price of $90.45.

In other Medtronic news, EVP Hooman Hakami sold 26,158 shares of the company’s stock in a transaction dated Friday, January 5th. The shares were sold at an average price of $85.00, for a total value of $2,223,430.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Richard Kuntz sold 78,526 shares of the company’s stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $86.21, for a total transaction of $6,769,726.46. Following the completion of the transaction, the vice president now owns 149,761 shares of the company’s stock, valued at approximately $12,910,895.81. The disclosure for this sale can be found here. In the last quarter, insiders sold 120,684 shares of company stock valued at $10,318,276. Insiders own 0.31% of the company’s stock.

Medtronic plc. (MDT) opened at $81.86 on Thursday. The firm has a market cap of $108,577.60, a PE ratio of 22.43, a price-to-earnings-growth ratio of 2.21 and a beta of 0.93. Medtronic plc. has a 1 year low of $76.51 and a 1 year high of $89.72. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.40 and a quick ratio of 2.05.

Medtronic (NYSE:MDT) last issued its quarterly earnings data on Tuesday, November 21st. The medical technology company reported $1.07 earnings per share for the quarter, topping analysts’ consensus estimates of $0.99 by $0.08. The business had revenue of $7.05 billion during the quarter, compared to the consensus estimate of $7.05 billion. Medtronic had a net margin of 16.93% and a return on equity of 12.63%. The company’s revenue was down 4.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.12 earnings per share. sell-side analysts expect that Medtronic plc. will post 4.76 EPS for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 19th. Shareholders of record on Friday, December 29th were given a $0.46 dividend. The ex-dividend date was Thursday, December 28th. This represents a $1.84 dividend on an annualized basis and a dividend yield of 2.25%. Medtronic’s dividend payout ratio (DPR) is currently 50.41%.

TRADEMARK VIOLATION NOTICE: This news story was posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at https://theolympiareport.com/2018/02/15/sentry-investment-management-llc-lowers-stake-in-medtronic-plc-mdt.html.

Medtronic Profile

Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic plc. (NYSE:MDT).

Institutional Ownership by Quarter for Medtronic (NYSE:MDT)

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.